NEWS: Chimeron Bio’s COVID-19 Vaccine Demonstrates Positive Pre-Clinical Results
Chimeron Bio’s unique ChaESAR platform leverages chimera encased self-amplifying RNA (saRNA) to achieve superior expression and broader dynamic range compared to other leading messenger RNA (mRNA) technologies.
We are developing a compelling portfolio of innovative and personalized saRNA-based medicines for people with serious diseases including cancer, infectious diseases, and rare genetic disorders, using our technology to achieve superior patient response at a lower dose.
July 30, 2020
The company feels confident about its repertoire of COVID-19 vaccine candidates and is preparing to start safety-toxicology assessment later this year.
July 1, 2020
The pharma and biotech community can help address not only unmet health needs, but also health inequities. Our role as scientists is critical right now.
See what makes ChaESAR™ a robust anti-viral approach.